Renal Cell Carcinoma Clinical Trial Landscape
Data updated: May 20, 2026
759 clinical trials tracked since 2008
Renal Cell Carcinoma (RCC) is a type of kidney cancer that originates in the lining of the kidney's small tubes. It is one of the most common cancers, with incidence varying by geography and demographics. The clinical trial landscape for RCC reflects ongoing efforts to improve treatment options and patient outcomes. Since 2008, 752 trials have been registered, with 295 currently active, meaning they are recruiting, enrolling, or active but not recruiting. Activity is heavily concentrated in early-phase trials, with 137 active Phase 1 and 176 active Phase 2 trials, compared to 35 active Phase 3 and 4 active Phase 4 trials. Merck is the leading industry sponsor with 6 active trials, followed by Bristol-Myers Squibb and Exelixis, each sponsoring 5 active trials. Peloton Therapeutics, a subsidiary of Merck, and AstraZeneca are also prominent sponsors, each with 4 active trials. The high volume of Phase 1 and 2 trials suggests a strong focus on novel therapeutic approaches and early-stage drug development in RCC.
301 active
/
759 total (since 2008)
139
Phase 1 Active
357 total
181
Phase 2 Active
433 total
34
Phase 3 Active
71 total
5
Phase 4 Active
21 total
Top Industry Sponsors
Sorted by active Active Done Failed
Merck 6 6 0
Bristol-Myers Squibb 5 14 3
Exelixis 5 2 1
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 4 1 0
AstraZeneca 4 0 0
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT03793166 ACTIVE NOT RECRUITING
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
National Cancer Institute (NCI) n=1,175
NCT07227402 RECRUITING
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Merck Sharp & Dohme LLC n=904
NCT06661720 RECRUITING
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Alliance for Clinical Trials in Oncology n=1,040
NCT05863351 ACTIVE NOT RECRUITING
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
ECOG-ACRIN Cancer Research Group n=472
NCT06500455 RECRUITING
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology n=269
+ 66 more Phase 3 trials — see full database below
Renal Cell Carcinoma — Trials Started by Year (last 10 years)
2016 43
2017 47
2018 49
2019 47
2020 46
2021 30
2022 43
2023 68
2024 49
2025 60
2026 38
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Merck 12
Bristol-Myers Squibb 22
Exelixis 8
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 5
AstraZeneca 4
Roche 10
Telix Pharmaceuticals (Innovations) Pty Limited 6
Arcus Biosciences, Inc. 4
HiFiBiO Therapeutics 3
OncoC4, Inc. 2
Active Trials by Phase
Phase 1 139
Phase 2 181
Phase 3 34
Phase 4 5
Enrollment Size Distribution
1-50 397
51-200 233
201-500 62
501-1k 27
1k+ 10
All Industry Sponsors
Sorted by active Active Done Failed
Merck 6 6 0
Bristol-Myers Squibb 5 14 3
Exelixis 5 2 1
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 4 1 0
AstraZeneca 4 0 0
Roche 3 4 3
Telix Pharmaceuticals (Innovations) Pty Limited 3 3 0
Arcus Biosciences, Inc. 3 1 0
HiFiBiO Therapeutics 2 0 1
OncoC4, Inc. 2 0 0
Regeneron 2 0 0
Chongqing Precision Biotech Co., Ltd 2 0 0
GI Innovation, Inc. 2 0 0
Jiangsu Hansoh Pharmaceutical Co., Ltd. 2 0 0
NGM Biopharmaceuticals, Inc 2 0 0
NCT03793166 ACTIVE NOT RECRUITING
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
National Cancer Institute (NCI) n=1,175
NCT07227402 RECRUITING
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Merck Sharp & Dohme LLC n=904
NCT06661720 RECRUITING
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Alliance for Clinical Trials in Oncology n=1,040
NCT05863351 ACTIVE NOT RECRUITING
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
ECOG-ACRIN Cancer Research Group n=472
NCT06500455 RECRUITING
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology n=269
NCT03055013 ACTIVE NOT RECRUITING
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
National Cancer Institute (NCI) n=819
NCT01575548 ACTIVE NOT RECRUITING
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
National Cancer Institute (NCI) n=129
NCT07011719 RECRUITING
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc. n=720
NCT07197580 RECRUITING
Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
Telix Pharmaceuticals (Innovations) Pty Limited n=40
NCT05738694 RECRUITING
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
ZHOU FANGJIAN n=298
NCT07000149 ACTIVE NOT RECRUITING
A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC
AstraZeneca n=1,116
NCT02811861 ACTIVE NOT RECRUITING
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
Eisai Inc. n=1,069
NCT07383441 NOT YET RECRUITING
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
SWOG Cancer Research Network n=718
NCT03873402 ACTIVE NOT RECRUITING
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
Bristol-Myers Squibb n=437
NCT06726421 RECRUITING
Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)
Sun Yat-sen University n=252
NCT07338981 NOT YET RECRUITING
The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.
Guliz Ozgun n=142
NCT05770037 RECRUITING
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
Cancer Research UK n=30
NCT01224288 ACTIVE NOT RECRUITING
Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
M.D. Anderson Cancer Center n=120
NCT04810078 ACTIVE NOT RECRUITING
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
Bristol-Myers Squibb n=681
NCT03937219 ACTIVE NOT RECRUITING
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Exelixis n=855
NCT07165418 NOT YET RECRUITING
A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI
Peking University Cancer Hospital & Institute n=116
NCT04510597 RECRUITING
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
SWOG Cancer Research Network n=364
NCT05678673 ACTIVE NOT RECRUITING
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
Exelixis n=317
NCT05796973 RECRUITING
Measuring Oncological Value of Exercise and Statin
Tampere University Hospital n=240
NCT03141177 ACTIVE NOT RECRUITING
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Bristol-Myers Squibb n=701
NCT05078047 RECRUITING
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
UNICANCER n=646
NCT05219318 ACTIVE NOT RECRUITING
Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors
University Hospital, Bordeaux n=22
NCT05043090 ACTIVE NOT RECRUITING
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
AstraZeneca n=148
NCT03592472 RECRUITING
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Xynomic Pharmaceuticals, Inc. n=413
NCT06364631 RECRUITING
CARE1 Pragmatic Clinical Trial
Gustave Roussy, Cancer Campus, Grand Paris n=1,250
NCT05522231 ACTIVE NOT RECRUITING
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
Hutchmed n=265
NCT06750419 RECRUITING
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
Telix Pharmaceuticals (Innovations) Pty Limited n=82
NCT06146777 NOT YET RECRUITING
Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy
First Affiliated Hospital, Sun Yat-Sen University n=468
NCT03288532 RECRUITING
Renal Adjuvant MultiPle Arm Randomised Trial
University College, London n=1,750
NCT04987203 COMPLETED
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc. n=343
NCT03142334 COMPLETED
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
Merck Sharp & Dohme LLC n=994
NCT02853331 COMPLETED
Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
Merck Sharp & Dohme LLC n=861
NCT07084909 WITHDRAWN
Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC
Lantheus Medical Imaging
NCT04394975 COMPLETED
Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer
Shanghai Junshi Bioscience Co., Ltd. n=421
NCT01120249 COMPLETED
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
SWOG Cancer Research Network n=1,545
NCT00930033 COMPLETED
Clinical Trial to Assess the Importance of Nephrectomy
Assistance Publique - Hôpitaux de Paris n=452
NCT03260894 COMPLETED
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation n=129
NCT02231749 COMPLETED
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Bristol-Myers Squibb n=1,390
NCT04588246 TERMINATED
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology n=19
NCT06903260 COMPLETED
Robot-assisted Partial Nephrectomy With and Without Mixed Reality (REALITATEM Study)
Hospital Moinhos de Vento n=45
NCT03013946 TERMINATED
Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy
AIO-Studien-gGmbH n=121
NCT03849118 COMPLETED
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study
Telix Pharmaceuticals (Innovations) Pty Limited n=300
NCT03024996 TERMINATED
A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
Hoffmann-La Roche n=778
NCT03729245 TERMINATED
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Nektar Therapeutics n=623
NCT02420821 COMPLETED
A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)
Hoffmann-La Roche n=915
NCT01668784 COMPLETED
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
Bristol-Myers Squibb n=821
NCT03408652 TERMINATED
Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies
Centre Leon Berard n=1
NCT01865747 COMPLETED
A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
Exelixis n=658
NCT01235962 COMPLETED
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
Novartis Pharmaceuticals n=1,538
NCT01076010 COMPLETED
An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).
AVEO Pharmaceuticals, Inc. n=277
NCT01030783 COMPLETED
A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc. n=517
NCT01198158 TERMINATED
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
National Cancer Institute (NCI) n=77
NCT00540969 TERMINATED
Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases
Alliance for Clinical Trials in Oncology n=3
NCT03693573 WITHDRAWN
A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma
Hoffmann-La Roche
NCT02535351 TERMINATED
Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano n=13
NCT00606632 COMPLETED
Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
Heidelberg Pharma AG n=226
NCT01582672 TERMINATED
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
Argos Therapeutics n=462
NCT01762592 WITHDRAWN
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
Heidelberg Pharma AG
NCT01265901 COMPLETED
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
Immatics Biotechnologies GmbH n=339
NCT02883153 COMPLETED
Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma
Radboud University Medical Center n=30
NCT01613846 COMPLETED
Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)
Technical University of Munich n=544
NCT00631371 COMPLETED
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Pfizer n=791
NCT01223027 COMPLETED
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Novartis Pharmaceuticals n=564
NCT02030717 COMPLETED
Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma
Umeå University n=120
NCT07516366 NOT YET RECRUITING
Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial
National Cancer Institute (NCI)
NCT04071223 ACTIVE NOT RECRUITING
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
National Cancer Institute (NCI)
NCT05831891 ACTIVE NOT RECRUITING
Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma
RenJi Hospital
NCT07293351 RECRUITING
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Bristol-Myers Squibb
NCT03866382 RECRUITING
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
NCT04981509 RECRUITING
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
National Cancer Institute (NCI)
NCT05411081 ACTIVE NOT RECRUITING
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
National Cancer Institute (NCI)
NCT07049926 RECRUITING
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Merck Sharp & Dohme LLC
NCT05805501 ACTIVE NOT RECRUITING
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Hoffmann-La Roche
NCT07571551 RECRUITING
Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma
Jinling Hospital, China
NCT07578025 NOT YET RECRUITING
Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
City of Hope Medical Center
NCT05661955 ACTIVE NOT RECRUITING
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
BeiGene
NCT07576725 NOT YET RECRUITING
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
NCT06035224 ACTIVE NOT RECRUITING
Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma
RenJi Hospital
NCT05155033 RECRUITING
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
National Cancer Institute (NCI)
NCT05363280 RECRUITING
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Advenchen Pharmaceuticals, LLC.
NCT04022343 ACTIVE NOT RECRUITING
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
Emory University
NCT05663710 RECRUITING
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
M.D. Anderson Cancer Center
NCT06835972 RECRUITING
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Memorial Sloan Kettering Cancer Center
NCT05327686 RECRUITING
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
NRG Oncology
NCT07037004 NOT YET RECRUITING
Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery
City of Hope Medical Center
NCT07188896 RECRUITING
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Brian Rini
NCT07043608 NOT YET RECRUITING
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
Kelly Fitzgerald, MD
NCT04006522 ACTIVE NOT RECRUITING
89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
James Brugarolas
NCT05361720 RECRUITING
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Vanderbilt-Ingram Cancer Center
NCT07551349 RECRUITING
Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma
Beijing Biotech
NCT03284385 ACTIVE NOT RECRUITING
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
National Cancer Institute (NCI)
NCT03682289 ACTIVE NOT RECRUITING
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
Rahul Aggarwal
NCT07115043 RECRUITING
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
AstraZeneca
NCT06284564 ACTIVE NOT RECRUITING
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
M.D. Anderson Cancer Center
NCT05969860 RECRUITING
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Mayo Clinic
NCT07227415 RECRUITING
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
NCT04393350 ACTIVE NOT RECRUITING
Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
Emory University
NCT07223424 RECRUITING
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Diwakar Davar
NCT06638931 RECRUITING
Agnostic Therapy in Rare Solid Tumors
Instituto do Cancer do Estado de São Paulo
NCT00918775 ACTIVE NOT RECRUITING
Follow-up After Metastasectomy in Patients With Kidney Cancer
M.D. Anderson Cancer Center
NCT06053658 RECRUITING
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
NCT01038778 ACTIVE NOT RECRUITING
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
NCT02867592 ACTIVE NOT RECRUITING
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
NCT06362369 RECRUITING
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
NCT05969496 RECRUITING
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
University of Colorado, Denver
NCT03401788 ACTIVE NOT RECRUITING
A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT05048212 RECRUITING
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
M.D. Anderson Cancer Center
NCT06099782 ACTIVE NOT RECRUITING
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
Merck Sharp & Dohme LLC
NCT05665361 RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
National Cancer Institute (NCI)
NCT05808608 ACTIVE NOT RECRUITING
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
Hao Zeng
NCT06376669 RECRUITING
Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06794229 RECRUITING
Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis
Qian Qin
NCT06863311 RECRUITING
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
Karie Runcie
NCT07510334 NOT YET RECRUITING
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Mayo Clinic
NCT03786796 RECRUITING
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT07123090 RECRUITING
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
Stephanie Berg
NCT05024214 RECRUITING
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
3D Medicines (Sichuan) Co., Ltd.
NCT07470840 NOT YET RECRUITING
SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma
Fujian Cancer Hospital
NCT07488572 ENROLLING BY INVITATION
Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study
Sun Yat-sen University
NCT07488533 ACTIVE NOT RECRUITING
Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma
Sun Yat-sen University
NCT07397611 RECRUITING
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
Dana-Farber Cancer Institute
NCT07239596 RECRUITING
Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT06708949 RECRUITING
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
NCT07469683 RECRUITING
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Yonsei University
NCT05269381 RECRUITING
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Mayo Clinic
NCT07077083 NOT YET RECRUITING
CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC
Massachusetts General Hospital
NCT02568267 ACTIVE NOT RECRUITING
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Hoffmann-La Roche
NCT05012371 ACTIVE NOT RECRUITING
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
M.D. Anderson Cancer Center
NCT05703854 RECRUITING
Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
M.D. Anderson Cancer Center
NCT06699602 RECRUITING
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
NCT06047379 RECRUITING
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
NCT07223541 RECRUITING
Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
University of Oklahoma
NCT01684397 ACTIVE NOT RECRUITING
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Roswell Park Cancer Institute
NCT07410676 RECRUITING
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Essen Biotech
NCT05641935 RECRUITING
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
john eisenbrey
NCT07389629 RECRUITING
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Sun Yat-sen University
NCT07386158 RECRUITING
Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC
Sun Yat-sen University
NCT01217931 ACTIVE NOT RECRUITING
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
M.D. Anderson Cancer Center
NCT04645680 ACTIVE NOT RECRUITING
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
M.D. Anderson Cancer Center
NCT03474497 ACTIVE NOT RECRUITING
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
Megan Daly, MD
NCT07077161 RECRUITING
Cabozantinib Dose Skipping as an Alternative to Dose Reductions
dr. Tom van der Hulle
NCT05468697 ACTIVE NOT RECRUITING
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
Merck Sharp & Dohme LLC
NCT04413123 ACTIVE NOT RECRUITING
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
Bradley A. McGregor, MD
NCT07292168 RECRUITING
A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1
Kidney Cancer Research Bureau
NCT02473536 ACTIVE NOT RECRUITING
Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC
University of Texas Southwestern Medical Center
NCT07346404 NOT YET RECRUITING
Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma
Assistance Publique - Hôpitaux de Paris
NCT06004336 RECRUITING
A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)
M.D. Anderson Cancer Center
NCT03228667 ACTIVE NOT RECRUITING
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
NCT05501054 ACTIVE NOT RECRUITING
Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.
M.D. Anderson Cancer Center
NCT05239533 ACTIVE NOT RECRUITING
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
Memorial Sloan Kettering Cancer Center
NCT04299646 RECRUITING
A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases
Centre Francois Baclesse
NCT07219576 RECRUITING
Retifanlimab and Ruxolitinib In Solid Malignancies
University of California, San Diego
NCT03541902 ACTIVE NOT RECRUITING
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
M.D. Anderson Cancer Center
NCT03587662 ACTIVE NOT RECRUITING
Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
M.D. Anderson Cancer Center
NCT07187778 RECRUITING
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
M.D. Anderson Cancer Center
NCT05830058 RECRUITING
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
City of Hope Medical Center
NCT00715442 ACTIVE NOT RECRUITING
Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
NCT07285044 RECRUITING
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
NCT06584435 ACTIVE NOT RECRUITING
A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer
Tianjin Medical University Second Hospital
NCT04198766 ACTIVE NOT RECRUITING
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
NCT03092856 ACTIVE NOT RECRUITING
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
University of Southern California
NCT04974671 RECRUITING
Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma
Yale University
NCT06265285 RECRUITING
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
NCT05263050 RECRUITING
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
NCT03595124 ACTIVE NOT RECRUITING
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
National Cancer Institute (NCI)
NCT06601296 RECRUITING
Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer
University of Texas Southwestern Medical Center
NCT07226544 NOT YET RECRUITING
Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer
City of Hope Medical Center
NCT04074967 ACTIVE NOT RECRUITING
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
Dan Zandberg
NCT03972657 RECRUITING
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Regeneron Pharmaceuticals
NCT03172754 ACTIVE NOT RECRUITING
Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
Fox Chase Cancer Center
NCT06005818 RECRUITING
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
University of Alabama at Birmingham
NCT07218692 NOT YET RECRUITING
RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
City of Hope Medical Center
NCT05931393 RECRUITING
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
University of Texas Southwestern Medical Center
NCT00722228 RECRUITING
Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
Hadassah Medical Organization
NCT03438708 ACTIVE NOT RECRUITING
Prior Axitinib as a Determinant of Outcome of Renal Surgery
University of California, San Diego
NCT05148546 ACTIVE NOT RECRUITING
Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer
The Netherlands Cancer Institute
NCT06730932 NOT YET RECRUITING
A Prospective，Single Arm, Multicenter Clinical Study of BTLA Monoclonal Antibody JS004 (B/T Lymphocyte Attenuator Factor Monoclonal Antibody) in Combination With Toripalimab in Patients With Unresectable or Advanced Renal Cell Carcinoma Who Had Failed Previous Immunotherapy
RenJi Hospital
NCT06245915 ACTIVE NOT RECRUITING
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
Arsenal Biosciences, Inc.
NCT03635892 ACTIVE NOT RECRUITING
A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
NCT07175480 RECRUITING
PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk
Jinling Hospital, China
NCT03647163 ACTIVE NOT RECRUITING
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
Vyriad, Inc.
NCT07172386 RECRUITING
Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC
Tianjin Medical University Second Hospital
NCT07172802 RECRUITING
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
GI Innovation, Inc.
NCT07167329 RECRUITING
Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial
José Claudio Casali da Rocha
NCT06866262 RECRUITING
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
University of Michigan Rogel Cancer Center
NCT06682793 RECRUITING
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
A2 Biotherapeutics Inc.
NCT07159191 NOT YET RECRUITING
Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
Peking Union Medical College Hospital
NCT06255223 RECRUITING
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
Jinling Hospital, China
NCT06307431 ACTIVE NOT RECRUITING
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
Merck Sharp & Dohme LLC
NCT06127238 ACTIVE NOT RECRUITING
Study of ST-1898 in Advanced Renal Cell Carcinoma
Beijing Scitech-Mq Pharmaceuticals Limited
NCT05319015 RECRUITING
Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus
University of Texas Southwestern Medical Center
NCT05864144 ACTIVE NOT RECRUITING
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
NCT07101900 ENROLLING BY INVITATION
68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses
Peking Union Medical College Hospital
NCT04090710 ACTIVE NOT RECRUITING
SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
Ontario Clinical Oncology Group (OCOG)
NCT07097935 RECRUITING
Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma
Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT02956798 ACTIVE NOT RECRUITING
SAbR For Oligometastatic Renal Cell Carcinoma
University of Texas Southwestern Medical Center
NCT07087158 NOT YET RECRUITING
A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma
Imbioray (Hangzhou) Biomedicine Co., Ltd.
NCT07047001 ACTIVE NOT RECRUITING
Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma
Dong Wen
NCT05286294 ACTIVE NOT RECRUITING
Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders
Oslo University Hospital
NCT03093688 RECRUITING
Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
Shanghai Public Health Clinical Center
NCT07023432 NOT YET RECRUITING
Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
M.D. Anderson Cancer Center
NCT06447103 RECRUITING
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
Jonsson Comprehensive Cancer Center
NCT04140526 ACTIVE NOT RECRUITING
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
OncoC4, Inc.
NCT06976021 NOT YET RECRUITING
Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy
Maria Sklodowska-Curie National Research Institute of Oncology
NCT04322955 RECRUITING
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
Mark Stein
NCT02306954 ACTIVE NOT RECRUITING
Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer
Providence Health & Services
NCT05256472 ACTIVE NOT RECRUITING
A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
Akeso
NCT06783348 NOT YET RECRUITING
Radiopharmaceutical Treatment of Advanced Kidney Cancer
European Organisation for Research and Treatment of Cancer - EORTC
NCT03634540 ACTIVE NOT RECRUITING
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT06730672 RECRUITING
An Exploratory Study on the Failure of Immunotherapy With Voronib Combined With Everolimus
Sun Yat-sen University
NCT05128487 ACTIVE NOT RECRUITING
A Study of NDI 1150-101 in Patients With Solid Tumors
Nimbus Saturn, Inc.
NCT05824975 RECRUITING
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
GI Innovation, Inc.
NCT05199272 ACTIVE NOT RECRUITING
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
23andMe, Inc.
NCT04787042 RECRUITING
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Simcha IL-18, Inc.
NCT05620134 ACTIVE NOT RECRUITING
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
NCT04913337 ACTIVE NOT RECRUITING
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals, Inc
NCT06613269 RECRUITING
68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.
Peking Union Medical College Hospital
NCT06577961 NOT YET RECRUITING
Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06523049 NOT YET RECRUITING
Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy
Hao Zeng
NCT05013099 ACTIVE NOT RECRUITING
Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
ImaginAb, Inc.
NCT06472895 NOT YET RECRUITING
A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma
Peking University Cancer Hospital & Institute
NCT02992912 ACTIVE NOT RECRUITING
Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours
Gustave Roussy, Cancer Campus, Grand Paris
NCT05024318 RECRUITING
NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma
Peter MacCallum Cancer Centre, Australia
NCT06265025 RECRUITING
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
GeneMedicine Co., Ltd.
NCT06279403 NOT YET RECRUITING
Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
RenJi Hospital
NCT05096390 RECRUITING
Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC
Centre Leon Berard
NCT06211790 RECRUITING
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
Fudan University
NCT05817903 RECRUITING
Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients
Consorzio Oncotech
NCT05798455 NOT YET RECRUITING
Evaluation of the Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Advanced Renal Cell Carcinoma
Tabriz University of Medical Sciences
NCT05768464 RECRUITING
Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NCT03294083 ACTIVE NOT RECRUITING
A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma
SillaJen, Inc.
NCT03308396 ACTIVE NOT RECRUITING
Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
Ajjai Alva, MD
NCT07593040 NOT YET RECRUITING
Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma
Vall d'Hebron Institute of Oncology
NCT07594106 NOT YET RECRUITING
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
Regeneron Pharmaceuticals
NCT04902040 TERMINATED
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
NCT06059014 COMPLETED
Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer
Centre Leon Berard
NCT06138496 COMPLETED
Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Sun Yat-sen University
NCT00814021 COMPLETED
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Institut Claudius Regaud
NCT03575611 SUSPENDED
Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma
M.D. Anderson Cancer Center
NCT02964078 COMPLETED
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT04904302 TERMINATED
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
M.D. Anderson Cancer Center
NCT03652298 TERMINATED
Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative Disease Progression and Partners
Centre Oscar Lambret
NCT03945773 COMPLETED
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
Ipsen
NCT06860386 SUSPENDED
Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
H. Lee Moffitt Cancer Center and Research Institute
NCT06114940 TERMINATED
Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO)
Jinling Hospital, China
NCT05721222 TERMINATED
Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
Genmab
NCT05487859 WITHDRAWN
Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)
University of Alabama at Birmingham
NCT05928806 SUSPENDED
Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
Michael B. Atkins, MD
NCT06716853 TERMINATED
A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma
Genenta Science
NCT05070247 TERMINATED
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
NCT04260802 TERMINATED
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
NCT06818305 TERMINATED
Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT
Jinling Hospital, China
NCT04704219 COMPLETED
Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)
Merck Sharp & Dohme LLC
NCT04779151 TERMINATED
Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab
Gustave Roussy, Cancer Campus, Grand Paris
NCT05795595 COMPLETED
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
CRISPR Therapeutics AG
NCT04955743 TERMINATED
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Yale University
NCT04370509 TERMINATED
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
University of California, San Francisco
NCT05935748 TERMINATED
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NiKang Therapeutics, Inc.
NCT05119335 TERMINATED
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
NiKang Therapeutics, Inc.
NCT03075423 COMPLETED
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC
Goethe University
NCT04758507 COMPLETED
Fecal Microbiota Transplantation to Improve Efficacy of Immune Checkpoint Inhibitors in Renal Cell Carcinoma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT05263245 COMPLETED
The Pharmacological Effects of Using Cabozantinib With a Light Breakfast
dr. Tom van der Hulle
NCT06361810 WITHDRAWN
PSMA Therapy and Immunotherapy in Kidney Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT07011849 WITHDRAWN
Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases
M.D. Anderson Cancer Center
NCT03685448 COMPLETED
ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
NCT03967522 COMPLETED
Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases
Centre Leon Berard
NCT05714553 TERMINATED
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
NCT03117309 COMPLETED
Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
Michael B. Atkins, MD
NCT03297593 COMPLETED
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
Swiss Cancer Institute
NCT02446860 TERMINATED
A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)
Royal Marsden NHS Foundation Trust
NCT04337970 COMPLETED
Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer
Memorial Sloan Kettering Cancer Center
NCT06389682 COMPLETED
Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM005 in Patients
Norroy Bioscience Co., LTD
NCT02440334 COMPLETED
Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation
Thomas Jefferson University
NCT04383210 TERMINATED
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
NCT03829501 TERMINATED
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
NCT03173560 COMPLETED
Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma
Eisai Inc.
NCT04267120 TERMINATED
Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
Washington University School of Medicine
NCT06884683 TERMINATED
Nivolumab Plus Metformin in Metastatic Renal Cell Carcinoma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT03149822 COMPLETED
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
University of Colorado, Denver
NCT04495894 TERMINATED
Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma
Emory University
NCT01767636 COMPLETED
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Mayo Clinic
NCT03190174 COMPLETED
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Sarcoma Oncology Research Center, LLC
NCT02724878 COMPLETED
Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Dana-Farber Cancer Institute
NCT03991130 TERMINATED
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
Gregory Daniels
NCT02761057 COMPLETED
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
National Cancer Institute (NCI)
NCT04068831 COMPLETED
Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
NCT01291420 COMPLETED
Dendritic Cell Vaccination for Patients with Solid Tumors
University Hospital, Antwerp
NCT01693822 COMPLETED
A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy
Institute of Cancer Research, United Kingdom
NCT03015740 COMPLETED
Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer
M.D. Anderson Cancer Center
NCT02639182 COMPLETED
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Astellas Pharma Global Development, Inc.
NCT03393936 TERMINATED
Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma
Shanghai PerHum Therapeutics Co., Ltd.
NCT04580836 WITHDRAWN
MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial
M.D. Anderson Cancer Center
NCT06648902 COMPLETED
Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue
Kidney Cancer Research Bureau
NCT02667886 COMPLETED
Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma
X4 Pharmaceuticals
NCT03108066 COMPLETED
MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT05485896 COMPLETED
Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC
Tianjin Medical University Second Hospital
NCT01263769 COMPLETED
Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
NCT03552380 TERMINATED
Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
Roberto Pili
NCT02431676 COMPLETED
Survivorship Promotion In Reducing IGF-1 Trial
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03696277 COMPLETED
SAbR For Oligo-Progressive Renal Cell Cancer.
University of Texas Southwestern Medical Center
NCT02978404 COMPLETED
Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
Centre hospitalier de l'Université de Montréal (CHUM)
NCT03562507 TERMINATED
Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma
University of Michigan Rogel Cancer Center
NCT03097328 COMPLETED
Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Bradley A. McGregor, MD
NCT06377722 TERMINATED
Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer
Fundacion Oncosur
NCT03311334 TERMINATED
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
NCT03126331 COMPLETED
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
Case Comprehensive Cancer Center
NCT03511391 COMPLETED
CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors
University Hospital, Ghent
NCT01524926 COMPLETED
CREATE: Cross-tumoral Phase 2 With Crizotinib
European Organisation for Research and Treatment of Cancer - EORTC
NCT02599324 COMPLETED
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Pharmacyclics LLC.
NCT02232646 WITHDRAWN
A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies
Sumitomo Pharma America, Inc.
NCT04021238 COMPLETED
Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging
UNC Lineberger Comprehensive Cancer Center
NCT02718066 COMPLETED
Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
HUYABIO International, LLC.
NCT04300140 TERMINATED
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Aravive, Inc.
NCT06090318 WITHDRAWN
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Rain Oncology Inc
NCT03680521 COMPLETED
Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
Mirati Therapeutics Inc.
NCT04203901 TERMINATED
Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
CoImmune
NCT01517243 COMPLETED
Phase II Study of Alternating Sunitinib and Temsirolimus
Dartmouth-Hitchcock Medical Center
NCT03207347 COMPLETED
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
NCT03200717 COMPLETED
Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment
Novartis Pharmaceuticals
NCT02855203 COMPLETED
Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours
Peter MacCallum Cancer Centre, Australia
NCT03576131 TERMINATED
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
Genmab
NCT03679767 COMPLETED
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
Incyte Corporation
NCT00788125 TERMINATED
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
City of Hope Medical Center
NCT01164228 COMPLETED
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
ECOG-ACRIN Cancer Research Group
NCT04535687 COMPLETED
Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NCT03637803 TERMINATED
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
4D pharma plc
NCT04603365 WITHDRAWN
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
Jonsson Comprehensive Cancer Center
NCT02853344 COMPLETED
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
Merck Sharp & Dohme LLC
NCT04118855 COMPLETED
Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
RenJi Hospital
NCT02019693 COMPLETED
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
National Cancer Institute (NCI)
NCT03428217 COMPLETED
CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma
Calithera Biosciences, Inc
NCT02771626 TERMINATED
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
Calithera Biosciences, Inc
NCT02983045 COMPLETED
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
Nektar Therapeutics
NCT03435640 TERMINATED
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Nektar Therapeutics
NCT02915783 COMPLETED
A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
Eisai Inc.
NCT04088500 TERMINATED
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
Bristol-Myers Squibb
NCT02923531 TERMINATED
Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma
X4 Pharmaceuticals
NCT03387514 TERMINATED
Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies
University of Wisconsin, Madison
NCT00830895 COMPLETED
RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)
Seoul National University Hospital
NCT01727336 TERMINATED
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
NCT02917772 COMPLETED
Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
AIO-Studien-gGmbH
NCT03163667 COMPLETED
CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)
Calithera Biosciences, Inc
NCT02089685 COMPLETED
Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)
Merck Sharp & Dohme LLC
NCT02489695 COMPLETED
Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma
Centre Leon Berard
NCT02432846 COMPLETED
Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)
Mendus
NCT01582009 TERMINATED
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
Roswell Park Cancer Institute
NCT02781506 TERMINATED
Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma
University of Texas Southwestern Medical Center
NCT01034631 COMPLETED
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Hoosier Cancer Research Network
NCT03029780 COMPLETED
An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma
Bristol-Myers Squibb
NCT01157091 COMPLETED
Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
City of Hope Medical Center
NCT01664182 COMPLETED
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
NCT01354431 COMPLETED
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
Bristol-Myers Squibb
NCT03655613 TERMINATED
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
Apollomics (Australia) Pty. Ltd.
NCT03633110 COMPLETED
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
Genocea Biosciences, Inc.
NCT03334409 TERMINATED
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
Academic and Community Cancer Research United
NCT01513187 COMPLETED
Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma
Spanish Oncology Genito-Urinary Group
NCT03875313 TERMINATED
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Calithera Biosciences, Inc
NCT03035630 WITHDRAWN
Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
Guru Sonpavde
NCT02178722 COMPLETED
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Incyte Corporation
NCT01399918 COMPLETED
Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Memorial Sloan Kettering Cancer Center
NCT01566747 COMPLETED
Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5
Cancer Trials Ireland
NCT00550277 COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma
SCRI Development Innovations, LLC
NCT03520231 COMPLETED
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
University Health Network, Toronto
NCT02724020 COMPLETED
MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
Millennium Pharmaceuticals, Inc.
NCT03013335 COMPLETED
Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen
UNICANCER
NCT03115801 TERMINATED
A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers
Weill Medical College of Cornell University
NCT01392183 COMPLETED
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
NCT03339219 COMPLETED
A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma
Takeda
NCT02959554 TERMINATED
Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control
AIO-Studien-gGmbH
NCT01896271 COMPLETED
High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
University of Texas Southwestern Medical Center
NCT01649180 TERMINATED
NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma
PrECOG, LLC.
NCT02989714 COMPLETED
Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer
University of Michigan Rogel Cancer Center
NCT03494816 COMPLETED
Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion
Scottish Clinical Trials Research Unit
NCT01147536 TERMINATED
Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
Agenus Inc.
NCT02118337 COMPLETED
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
MedImmune LLC
NCT02581384 TERMINATED
Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors
Dana-Farber Cancer Institute
NCT01185366 TERMINATED
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
NCT00853125 TERMINATED
Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
Rutgers, The State University of New Jersey
NCT03463681 COMPLETED
A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NCT02960906 COMPLETED
A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
NCT01253668 TERMINATED
Brivanib Metastatic Renal Cell Carcinoma
Abramson Cancer Center at Penn Medicine
NCT03065179 COMPLETED
SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients
University of Texas Southwestern Medical Center
NCT02019576 COMPLETED
Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib
Sunnybrook Health Sciences Centre
NCT00827359 COMPLETED
Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
Beth Israel Deaconess Medical Center
NCT01835158 COMPLETED
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
National Cancer Institute (NCI)
NCT02495103 TERMINATED
Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
National Cancer Institute (NCI)
NCT02853162 TERMINATED
Ablative tReatment of Inoperable REnal Cell Carcinoma Using STereotactic Body Radiotherapy (ARREST-study)
UMC Utrecht
NCT02082210 COMPLETED
A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Eli Lilly and Company
NCT01798446 COMPLETED
A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus
Seoul National University Hospital
NCT04262375 WITHDRAWN
A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION
University Health Network, Toronto
NCT01673386 TERMINATED
A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC
AVEO Pharmaceuticals, Inc.
NCT01297244 COMPLETED
A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc.
NCT01806064 TERMINATED
Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma
Tracon Pharmaceuticals Inc.
NCT03540199 WITHDRAWN
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer
Fuda Cancer Hospital, Guangzhou
NCT03598816 WITHDRAWN
PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma
Washington University School of Medicine
NCT04462445 COMPLETED
Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NCT00853372 COMPLETED
AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib
Amgen
NCT02187302 COMPLETED
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
NewLink Genetics Corporation
NCT03927248 WITHDRAWN
PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer
HealthPartners Institute
NCT01355562 WITHDRAWN
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
Loma Linda University
NCT01510119 COMPLETED
Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma
Abramson Cancer Center at Penn Medicine
NCT01775930 COMPLETED
Carfilzomib in Refractory Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
NCT02060370 COMPLETED
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
M.D. Anderson Cancer Center
NCT01392352 TERMINATED
HYPAZ: Hypertension Induced by Pazopanib
Cambridge University Hospitals NHS Foundation Trust
NCT01550367 COMPLETED
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
Leonard Appleman
NCT01984242 COMPLETED
A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma
Hoffmann-La Roche
NCT02335918 COMPLETED
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Celldex Therapeutics
NCT00975806 TERMINATED
Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma
Celgene
NCT02700568 COMPLETED
Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors
Kidney Cancer Research Bureau
NCT03379012 COMPLETED
Testosterone in Metastatic Renal Cell Carcinoma Patients
Kidney Cancer Research Bureau
NCT01239342 TERMINATED
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
National Cancer Institute (NCI)
NCT00709995 COMPLETED
A Study for Participants With Metastatic Renal Cell Carcinoma
Eli Lilly and Company
NCT02447887 TERMINATED
Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)
Fox Chase Cancer Center
NCT02141490 COMPLETED
Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers
National Cancer Institute (NCI)
NCT01391130 TERMINATED
A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Eli Lilly and Company
NCT01136733 COMPLETED
A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
Eisai Inc.
NCT01731158 COMPLETED
Sequential Therapy in Metastatic Renal Cell Carinoma
Central European Society for Anticancer Drug Research
NCT03323710 WITHDRAWN
Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma
Military Institute od Medicine National Research Institute
NCT01441414 TERMINATED
PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Pfizer
NCT01688973 COMPLETED
Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT01762150 COMPLETED
Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma
Peking University Cancer Hospital & Institute
NCT02669914 TERMINATED
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Washington University School of Medicine
NCT00896454 COMPLETED
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Amgen
NCT02763761 WITHDRAWN
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
Bristol-Myers Squibb
NCT01158222 COMPLETED
Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Case Comprehensive Cancer Center
NCT01158521 COMPLETED
Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
Case Comprehensive Cancer Center
NCT01727089 COMPLETED
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
NCT01482949 TERMINATED
A Rollover Protocol for Subjects Previously Treated With AGS-003
Argos Therapeutics
NCT02626754 TERMINATED
A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population
vghtpe user
NCT01831973 COMPLETED
A Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Advanced/Metastatic RCC Patients
Taiwan Liposome Company
NCT03149159 WITHDRAWN
Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab
Medical University of South Carolina
NCT01361113 COMPLETED
Neoadjuvant Pazopanib in Renal Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
NCT00923130 COMPLETED
Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
NCT01499121 COMPLETED
Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule
Sunnybrook Health Sciences Centre
NCT00782275 COMPLETED
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Beth Israel Deaconess Medical Center
NCT01108445 COMPLETED
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
Duke University
NCT00769990 WITHDRAWN
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
Masonic Cancer Center, University of Minnesota
NCT02122003 TERMINATED
Second Line Sorafenib After Pazopanib in Patients With RCC
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NCT01784978 TERMINATED
Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer
Associació per a la Recerca Oncologica, Spain
NCT00923845 COMPLETED
Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer
National Cancer Institute (NCI)
NCT02089802 TERMINATED
Optimizing Pazopanib Exposure in RCC Patients
Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.
NCT01176500 WITHDRAWN
A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors
National Cancer Institute (NCI)
NCT00934440 TERMINATED
A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma
University of Kansas Medical Center
NCT02071641 TERMINATED
Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma
Amsterdam UMC, location VUmc
NCT01141569 COMPLETED
A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy
National Cancer Institute (NCI)
NCT02607553 COMPLETED
Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA
GenSpera, Inc.
NCT01264341 TERMINATED
Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma
Hellenic Cooperative Oncology Group
NCT01441765 TERMINATED
PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine
Beth Israel Deaconess Medical Center
NCT00672178 TERMINATED
Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC)
Duke University
NCT00903175 COMPLETED
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma
Novartis Pharmaceuticals
NCT01715935 COMPLETED
Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
NCT01442090 COMPLETED
Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy
Genentech, Inc.
NCT01491672 COMPLETED
Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
Novartis Pharmaceuticals
NCT01925118 TERMINATED
Irradiated Donor Lymphocyte Infusion Plus High-dose IL-2
Seoul National University Hospital
NCT00556205 WITHDRAWN
Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma
Massachusetts General Hospital
NCT00831480 TERMINATED
Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal
Linda C. Higgins
NCT01062178 COMPLETED
Efficacy of Ultrasound Contrast Agent to Assess Renal Masses
University Health Network, Toronto
NCT01888042 TERMINATED
Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer
Gustave Roussy, Cancer Campus, Grand Paris
NCT01762033 TERMINATED
A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma
Lpath, Inc.
NCT00913913 TERMINATED
Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients
Dartmouth-Hitchcock Medical Center
NCT00704938 TERMINATED
Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
National Institutes of Health Clinical Center (CC)
NCT01342627 TERMINATED
Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma
Centro di Riferimento Oncologico - Aviano
NCT01100242 TERMINATED
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
New Mexico Cancer Research Alliance
NCT02002312 COMPLETED
Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer
Radboud University Medical Center
NCT00601926 TERMINATED
Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
Paul Monk
NCT00731211 COMPLETED
Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
SCRI Development Innovations, LLC
NCT01720693 TERMINATED
Novel Controlled Hypo-Perfusion Technique in Partial Nephrectomy
University Health Network, Toronto
NCT00918281 COMPLETED
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
GE Healthcare
NCT00684996 TERMINATED
Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
National Cancer Institute (NCI)
NCT00557830 TERMINATED
Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Accelerated Community Oncology Research Network
NCT00678119 COMPLETED
Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment
Argos Therapeutics
NCT00619268 COMPLETED
Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma
Centre Leon Berard
NCT01070186 WITHDRAWN
Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma
Jonsson Comprehensive Cancer Center
NCT00848640 COMPLETED
Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma
Egyptian Foundation For Cancer Research
NCT06673329 RECRUITING
Brodalumab in the Treatment of Immune-Related Adverse Events
Brian Henick, MD
NCT02496208 ACTIVE NOT RECRUITING
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
National Cancer Institute (NCI)
NCT07419841 RECRUITING
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Compass Therapeutics
NCT02298959 ACTIVE NOT RECRUITING
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
NCT07297667 NOT YET RECRUITING
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Canadian Cancer Trials Group
NCT07128680 RECRUITING
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
City of Hope Medical Center
NCT05581004 RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
NCT07195682 RECRUITING
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Bristol-Myers Squibb
NCT07564232 NOT YET RECRUITING
Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
NCT05536141 RECRUITING
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Arcus Biosciences, Inc.
NCT03354390 ACTIVE NOT RECRUITING
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma
National Heart, Lung, and Blood Institute (NHLBI)
NCT06147037 RECRUITING
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
AstraZeneca
NCT04388852 ACTIVE NOT RECRUITING
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
M.D. Anderson Cancer Center
NCT06966024 RECRUITING
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Deciphera Pharmaceuticals, LLC
NCT06049576 ACTIVE NOT RECRUITING
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
City of Hope Medical Center
NCT06819293 RECRUITING
IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma
Grit Biotechnology
NCT06026410 RECRUITING
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Kura Oncology, Inc.
NCT06582017 RECRUITING
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics Inc
NCT05858736 ACTIVE NOT RECRUITING
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
OncoC4, Inc.
NCT07401875 RECRUITING
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
M.D. Anderson Cancer Center
NCT05891171 ACTIVE NOT RECRUITING
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Arcus Biosciences, Inc.
NCT04514484 ACTIVE NOT RECRUITING
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
NCT05176483 RECRUITING
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Exelixis
NCT07300241 RECRUITING
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Neomorph, Inc
NCT05122546 ACTIVE NOT RECRUITING
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
City of Hope Medical Center
NCT05433142 RECRUITING
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Xencor, Inc.
NCT07297160 NOT YET RECRUITING
CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors
Baylor College of Medicine
NCT07160335 RECRUITING
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
Shanghai Henlius Biotech
NCT05239143 ACTIVE NOT RECRUITING
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Poseida Therapeutics, Inc.
NCT02950766 ACTIVE NOT RECRUITING
NeoVax Plus Ipilimumab in Renal Cell Carcinoma
Patrick Ott, MD, PhD
NCT02432963 ACTIVE NOT RECRUITING
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
NCT06234605 RECRUITING
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
HiberCell, Inc.
NCT05092373 RECRUITING
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
M.D. Anderson Cancer Center
NCT05030506 ACTIVE NOT RECRUITING
A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
Merck Sharp & Dohme LLC
NCT05856981 RECRUITING
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Sairopa B.V.
NCT03983954 ACTIVE NOT RECRUITING
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
NCT07252661 NOT YET RECRUITING
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
AccSalus Biosciences, Inc.
NCT06332755 RECRUITING
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
LG Chem
NCT05238883 ACTIVE NOT RECRUITING
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
NCT05789069 ACTIVE NOT RECRUITING
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
NCT06132945 ACTIVE NOT RECRUITING
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain
Memorial Sloan Kettering Cancer Center
NCT04495257 ACTIVE NOT RECRUITING
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
Yale University
NCT03589339 ACTIVE NOT RECRUITING
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Nanobiotix
NCT05783622 RECRUITING
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Janux Therapeutics
NCT07181720 RECRUITING
CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
Chongqing Precision Biotech Co., Ltd
NCT04696731 ACTIVE NOT RECRUITING
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Allogene Therapeutics
NCT07187869 NOT YET RECRUITING
Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
M.D. Anderson Cancer Center
NCT07179770 RECRUITING
Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)
NYU Langone Health
NCT06805825 RECRUITING
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility, Inc.
NCT04163289 ACTIVE NOT RECRUITING
Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NCT05653882 ACTIVE NOT RECRUITING
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
Asher Biotherapeutics, Inc.
NCT03170960 ACTIVE NOT RECRUITING
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Exelixis
NCT03872947 ACTIVE NOT RECRUITING
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
NCT04707248 ACTIVE NOT RECRUITING
A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
Daiichi Sankyo
NCT04522323 ACTIVE NOT RECRUITING
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
MedImmune LLC
NCT07062549 RECRUITING
Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02974738 ACTIVE NOT RECRUITING
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT05518253 RECRUITING
A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
Weijia Fang, MD
NCT05704985 ACTIVE NOT RECRUITING
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
NCT05967533 RECRUITING
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
University of California, Davis
NCT06870279 NOT YET RECRUITING
A Clinical Research of CD70-targeted CAR-NKT Cells (CGC738) Therapy in RCC
RenJi Hospital
NCT05759923 RECRUITING
First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours
Molecure S.A.
NCT03212404 ACTIVE NOT RECRUITING
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
NCT03845166 ACTIVE NOT RECRUITING
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Exelixis
NCT05215574 ACTIVE NOT RECRUITING
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
NCT06259552 RECRUITING
A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
SparX Biotech(Jiangsu) Co., Ltd.
NCT05867303 ACTIVE NOT RECRUITING
A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
RemeGen Co., Ltd.
NCT06553339 RECRUITING
A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT06321250 RECRUITING
A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma
Jemincare
NCT02293980 ACTIVE NOT RECRUITING
A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT06399419 RECRUITING
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
Osel, Inc.
NCT05354102 ACTIVE NOT RECRUITING
A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128
Biomica Ltd.
NCT05868174 RECRUITING
Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors
Telix Pharmaceuticals (Innovations) Pty Limited
NCT06383507 NOT YET RECRUITING
A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors
Zhejiang University
NCT06010875 RECRUITING
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
Chongqing Precision Biotech Co., Ltd
NCT05698238 NOT YET RECRUITING
Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours
Mabpro, a.s.
NCT05861947 TERMINATED
A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies
Aurigene Discovery Technologies Limited
NCT03798626 COMPLETED
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis Pharmaceuticals
NCT04234113 TERMINATED
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
SOTIO Biotech AG
NCT06580938 TERMINATED
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
Pfizer
NCT06546553 TERMINATED
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Pfizer
NCT01625351 COMPLETED
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
St. Jude Children's Research Hospital
NCT06840548 COMPLETED
A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer
Philogen S.p.A.
NCT06649682 SUSPENDED
68Ga-NYM096/177Lu-NYM096 in Metastatic ccRCC
Peking Union Medical College Hospital
NCT06626256 WITHDRAWN
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
NCT03260504 TERMINATED
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
University of Washington
NCT06052852 TERMINATED
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
NCT04374877 COMPLETED
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
NCT05229601 TERMINATED
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
NCT04272034 TERMINATED
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
NCT05293496 COMPLETED
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
MacroGenics
NCT04169711 COMPLETED
Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma
Arrowhead Pharmaceuticals
NCT06285097 TERMINATED
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Pfizer
NCT05585034 COMPLETED
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Xencor, Inc.
NCT02903914 COMPLETED
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Incyte Corporation
NCT06299163 TERMINATED
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Numab Therapeutics AG
NCT05788484 COMPLETED
A Study of CDX-585 in Patients With Advanced Malignancies
Celldex Therapeutics
NCT06191796 TERMINATED
Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
Exelixis
NCT02419495 TERMINATED
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
NCT04152018 TERMINATED
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Pfizer
NCT02318771 COMPLETED
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT04301011 TERMINATED
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
Turnstone Biologics, Corp.
NCT03894618 COMPLETED
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Shattuck Labs, Inc.
NCT05909995 TERMINATED
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
Incyte Corporation
NCT01638533 COMPLETED
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
NCT04438083 TERMINATED
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)
CRISPR Therapeutics AG
NCT03549000 TERMINATED
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Novartis Pharmaceuticals
NCT02619253 COMPLETED
Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma
Nabil Adra
NCT02009449 COMPLETED
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
Eli Lilly and Company
NCT01672775 COMPLETED
A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
Agensys, Inc.
NCT06034860 TERMINATED
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Molecular Templates, Inc.
NCT03809624 TERMINATED
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
Inhibrx Biosciences, Inc
NCT05641545 TERMINATED
IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients
SLK Kliniken Heilbronn GmbH
NCT04628780 TERMINATED
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
Pfizer
NCT05769959 TERMINATED
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
Hoffmann-La Roche
NCT03752398 COMPLETED
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
Xencor, Inc.
NCT03502330 COMPLETED
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
Yale University
NCT03829111 COMPLETED
CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer
City of Hope Medical Center
NCT03200587 COMPLETED
Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)
University of Utah
NCT03905889 TERMINATED
A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma
Brown University
NCT03621982 TERMINATED
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
ADC Therapeutics S.A.
NCT04518046 COMPLETED
Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
Mirati Therapeutics Inc.
NCT03629756 COMPLETED
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Arcus Biosciences, Inc.
NCT04429321 TERMINATED
Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
Abramson Cancer Center at Penn Medicine
NCT03329950 COMPLETED
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
NCT02762006 COMPLETED
Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
Moshe Ornstein
NCT05121948 TERMINATED
A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
HiberCell, Inc.
NCT04834778 COMPLETED
A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)
HiberCell, Inc.
NCT04540705 COMPLETED
A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread
Bristol-Myers Squibb
NCT05861778 COMPLETED
Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma
Telix Pharmaceuticals (Innovations) Pty Limited
NCT03229278 COMPLETED
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Rutgers, The State University of New Jersey
NCT02498665 COMPLETED
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
NCT02386826 COMPLETED
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
SCRI Development Innovations, LLC
NCT03829436 COMPLETED
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Tempest Therapeutics
NCT04440943 COMPLETED
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Celldex Therapeutics
NCT03841110 COMPLETED
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
NCT03758781 COMPLETED
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
NCT05800106 COMPLETED
A Bioequivalence Study of Sunitinib Malate Capsules.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT03849469 COMPLETED
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
Xencor, Inc.
NCT03775850 COMPLETED
A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
Evelo Biosciences, Inc.
NCT02264548 COMPLETED
A Phase I Evaluating Integration of HypofractionatedStudy Renal Ablative Radiotherapy
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NCT03063762 COMPLETED
Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Hoffmann-La Roche
NCT04430842 COMPLETED
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
NCT03517488 COMPLETED
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Xencor, Inc.
NCT01975831 COMPLETED
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
Ludwig Institute for Cancer Research
NCT00520533 TERMINATED
Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
Ludwig Institute for Cancer Research
NCT04060342 TERMINATED
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
NCT01061411 COMPLETED
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery
Roswell Park Cancer Institute
NCT02071862 COMPLETED
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Calithera Biosciences, Inc
NCT04596033 TERMINATED
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Genocea Biosciences, Inc.
NCT02035358 COMPLETED
Immunotherapy Study for Metastatic Renal Cell Cancer
NewLink Genetics Corporation
NCT02646748 COMPLETED
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
Incyte Corporation
NCT03138538 TERMINATED
M8891 First in Human in Solid Tumors
EMD Serono Research & Development Institute, Inc.
NCT02526017 COMPLETED
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Five Prime Therapeutics, Inc.
NCT00967577 COMPLETED
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
Weill Medical College of Cornell University
NCT00730639 COMPLETED
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
Bristol-Myers Squibb
NCT01472081 COMPLETED
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
Bristol-Myers Squibb
NCT03319459 COMPLETED
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Fate Therapeutics
NCT03652077 COMPLETED
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
NCT04496089 COMPLETED
Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC
Telix Pharmaceuticals (Innovations) Pty Limited
NCT01826877 COMPLETED
Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer
Jonsson Comprehensive Cancer Center
NCT02133742 COMPLETED
A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer
Pfizer
NCT03189186 WITHDRAWN
Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas
University of California, Irvine
NCT01482156 COMPLETED
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01152801 COMPLETED
Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer
Novartis Pharmaceuticals
NCT02947152 TERMINATED
HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma
Novartis Pharmaceuticals
NCT03538028 COMPLETED
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Biosciences International Sàrl
NCT02595918 TERMINATED
Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery
National Cancer Institute (NCI)
NCT04260360 WITHDRAWN
Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma
NanOlogy, LLC
NCT02575222 COMPLETED
Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03343613 TERMINATED
A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
Eli Lilly and Company
NCT02837991 TERMINATED
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
Celldex Therapeutics
NCT02223052 COMPLETED
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
NCT02390843 COMPLETED
Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors
Emory University
NCT02406521 COMPLETED
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
Dana-Farber Cancer Institute
NCT01497444 COMPLETED
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
NCT02795819 TERMINATED
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
Virginia Commonwealth University
NCT01184326 COMPLETED
Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
Dana-Farber Cancer Institute
NCT03427476 COMPLETED
CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma
Cancer Targeted Technology
NCT00923390 TERMINATED
Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor
National Cancer Institute (NCI)
NCT02867332 WITHDRAWN
PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.
Peking University
NCT01115803 TERMINATED
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Eli Lilly and Company
NCT00923520 COMPLETED
A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies
National Cancer Institute (NCI)
NCT02650635 TERMINATED
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
Mayo Clinic
NCT01625936 COMPLETED
CRLX101 Plus Bevacizumab in Advanced RCC
Abramson Cancer Center at Penn Medicine
NCT02386111 TERMINATED
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Celldex Therapeutics
NCT02835833 COMPLETED
Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
University of Alabama at Birmingham
NCT02543645 TERMINATED
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Celldex Therapeutics
NCT01012362 TERMINATED
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
NCT01727076 COMPLETED
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
National Cancer Institute (NCI)
NCT01943188 TERMINATED
Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer
Stanford University
NCT02410174 TERMINATED
To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma Tumors
Beth Israel Medical Center
NCT01144169 TERMINATED
Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma
University of Pittsburgh
NCT01522820 COMPLETED
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Roswell Park Cancer Institute
NCT01829971 TERMINATED
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
Mirna Therapeutics, Inc.
NCT01283048 COMPLETED
Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma
Toni Choueiri, MD
NCT01202032 COMPLETED
Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors
Centre Leon Berard
NCT00671411 COMPLETED
Evaluating Renal Masses Using Ultrasound Intravenous Microbubble Contrast
Memorial Sloan Kettering Cancer Center
NCT00625456 COMPLETED
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
Jennerex Biotherapeutics
NCT01122615 COMPLETED
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
M.D. Anderson Cancer Center
NCT00747305 TERMINATED
Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery
Harry Drabkin
NCT01525017 COMPLETED
A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer
Mendus
NCT01548482 COMPLETED
Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT00589550 TERMINATED
PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer
Thomas Olencki
NCT00753415 COMPLETED
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
Merck Sharp & Dohme LLC
NCT00788060 COMPLETED
A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma
Daniel George, MD
NCT01131234 COMPLETED
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT01243359 COMPLETED
Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies
National Cancer Institute (NCI)
NCT00890747 COMPLETED
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
National Cancer Institute (NCI)
NCT01048892 COMPLETED
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
Children's Oncology Group
NCT01677390 TERMINATED
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
Seagen Inc.
NCT01100619 COMPLETED
A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors
Exelixis
NCT00635791 COMPLETED
Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
University of Colorado, Denver
NCT00659568 COMPLETED
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
London Health Sciences Centre
NCT00944905 COMPLETED
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
Bristol-Myers Squibb
NCT00656734 COMPLETED
Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.
Bristol-Myers Squibb
NCT01114230 COMPLETED
A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer
Astellas Pharma Inc
NCT01254838 COMPLETED
Novel Peptide Vaccination for Patients With Advanced Renal Cell Carcinoma
Iwate Medical University
NCT00625768 COMPLETED
Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
Antisoma Research
NCT07405086 RECRUITING
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
NCT07028125 RECRUITING
Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma
Centre Francois Baclesse
NCT06934057 RECRUITING
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
Gustave Roussy, Cancer Campus, Grand Paris
NCT06903312 RECRUITING
Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT03824808 TERMINATED
Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery
University of Missouri-Columbia
NCT02982954 COMPLETED
A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer
Bristol-Myers Squibb
NCT02596035 COMPLETED
An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
Bristol-Myers Squibb
NCT00414765 COMPLETED
Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
Novartis Pharmaceuticals
NCT02570789 TERMINATED
Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
NCT01206764 COMPLETED
A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
Novartis Pharmaceuticals
NCT02338570 TERMINATED
Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)
Mario Negri Institute for Pharmacological Research
NCT01266837 COMPLETED
Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)
iOMEDICO AG
NCT01521715 COMPLETED
First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
iOMEDICO AG
NCT01514448 COMPLETED
Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
Novartis Pharmaceuticals
NCT02988219 COMPLETED
Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method
Medical University of Warsaw
NCT00930345 TERMINATED
Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
Assistance Publique - Hôpitaux de Paris
NCT01486550 TERMINATED
Hydroxyethyl Starch and Renal Function After Laparoscopic Nephrectomy
Regional Hospital Holstebro
NCT02056587 COMPLETED
Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment
Kidney Cancer Research Bureau
Full Renal Cell Carcinoma Pipeline
Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.
Unlock with ProData: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only